Are there any side effects from combining osimertinib and cabozantinib?

As two targeted drugs, osimertinib and cabozantinib may produce certain side effects when used alone, so side effects may also occur when they are used in combination.

Osimertinib, as an anti-tumor targeted drug, is often used to treat locally advanced or metastatic non-small cell lung cancer and other diseases. However, some patients may experience multiple adverse reactions while taking osimertinib. These adverse reactions are mainly manifested in the skin, digestive system, respiratory system and cardiovascular system. For example, symptoms such as blisters, erosion, scabs, and desquamation may appear on the skin; the digestive system may experience symptoms such as loss of appetite, abdominal pain, and diarrhea; and the respiratory system may experience complications such as interstitial lung disease and pneumonia. In addition, the cardiovascular system may also have serious adverse reactions such as prolonged electrocardiogram QT interval, decreased cardiac ejection fraction, and heart failure.

Cabozantinib is another multi-target tyrosine kinase inhibitor that also has certain side effects. Common adverse reactions include diarrhea, stomatitis, hand-foot syndrome, etc. In addition, cabozantinib may also cause symptoms such as hypertension, bleeding, and proteinuria.

When osimertinib and cabozantinib are used together, there may be an increased risk of adverse reactions as both drugs have certain side effects. These adverse reactions may include, but are not limited to, the symptoms mentioned above. Specific side effects vary from individual to individual and may be exacerbated with increased drug dosage and prolonged combined use.

Therefore, when using the combined treatment regimen of osimertinib and cabozantinib, doctors should closely monitor the patient's physical condition and adjust the drug dosage and treatment plan in a timely manner to reduce the incidence and severity of adverse reactions. At the same time, patients should also actively cooperate with doctors’ treatment recommendations and promptly report any discomfort or abnormal reactions to ensure the safety and effectiveness of treatment.